NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Cancer Vaccine Week


Susan Hasty, Publisher
Table of Contents . . . December 22nd, 2008
Non-Subscriber - Summaries Only
Related Areas: Other Issues in Cancer Vaccine Week | Other Publications

Emory University - Blocking immune inhibitor improves response to HIV-like virus, prolongs survival in monkeys

Cancer Vaccines - Data from Osaka University, Medical Department provide new insights into cancer vaccines

Cancer Vaccines - Studies from Wayne State University update current data on cancer vaccines

DNA Vaccines - Study results from P. Chiarella et al provide new insights into DNA vaccines

Immunotherapy - Reports outline immunotherapy study findings from Curtin University of Technology

Salmonellosis - University of California publishes research in salmonellosis

Cancer Vaccines - Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden



Return to Top of Page

-----------------------
PR Login